Use of recombinant human granulocyte-macrophage colony-stimulating factor in graft failure after bone marrow transplantation
Authors:
Open Access
- 1 July 1990
- journal article
- Published by American Society of Hematology in Blood
- Vol. 76 (1) , 245-253
Abstract
The effect of recombinant human granulocyte-macrophage colony- stimulating factor (rhGM-CSF) was evaluated in 37 patients with marrow graft failure after allogeneic (n = 15), autologous (n = 21), or syngeneic (n = 1) bone marrow transplantation. rhGM-CSF was administered by 2-hour infusion at doses between 60 and 1,000 micrograms/m2/d for 14 or 21 days. At doses of less than 500 micrograms/m2, rhGM-CSF was well-tolerated and did not exacerbate graft- versus-host disease in allogeneic transplant recipients. No patient with myelogenous leukemia relapsed while receiving rhGM-CSF. Twenty-one patients reached an absolute neutrophil count (ANC) greater than or equal to 0.5 x 10(9)/L within 2 weeks of starting therapy while 16 did not. None of seven patients who received chemically purged autologous marrow grafts responded to rhGM-CSF. The survival rates of GM-CSF- treated patients were significantly better than those of a historical control group.Keywords
This publication has 4 references indexed in Scilit:
- Effect of HLA Compatibility on Engraftment of Bone Marrow Transplants in Patients with Leukemia or LymphomaNew England Journal of Medicine, 1989
- Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Hematopoietic Reconstitution after High-Dose Chemotherapy and Autologous Bone Marrow TransplantationNew England Journal of Medicine, 1988
- Production of lymphocyte-activating factor (Interleukin 1) by macrophages activated with colony-stimulating factors.The Journal of Immunology, 1980
- Participation of lymphocyte activating factor (Interleukin 1) in the induction of cytotoxic T cell responses.The Journal of Immunology, 1980